%0 Journal Article
%T PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer.
%A Zhu M
%A Wang Y
%A Lu T
%A Guo J
%A Li L
%A Hsieh MH
%A Gopal P
%A Han Y
%A Fujiwara N
%A Wallace DP
%A Yu ASL
%A Fang X
%A Ransom C
%A Verschleisser S
%A Hsiehchen D
%A Hoshida Y
%A Singal AG
%A Yopp A
%A Wang T
%A Zhu H
%J Cell Metab
%V 0
%N 0
%D 2024 Jun 13
%M 38901424
%F 31.373
%R 10.1016/j.cmet.2024.05.015
%X Somatic mutations in non-malignant tissues are selected for because they confer increased clonal fitness. However, it is uncertain whether these clones can benefit organ health. Here, ultra-deep targeted sequencing of 150 liver samples from 30 chronic liver disease patients revealed recurrent somatic mutations. PKD1 mutations were observed in 30% of patients, whereas they were only detected in 1.3% of hepatocellular carcinomas (HCCs). To interrogate tumor suppressor functionality, we perturbed PKD1 in two HCC cell lines and six in vivo models, in some cases showing that PKD1 loss protected against HCC, but in most cases showing no impact. However, Pkd1 haploinsufficiency accelerated regeneration after partial hepatectomy. We tested Pkd1 in fatty liver disease, showing that Pkd1 loss was protective against steatosis and glucose intolerance. Mechanistically, Pkd1 loss selectively increased mTOR signaling without SREBP-1c activation. In summary, PKD1 mutations exert adaptive functionality on the organ level without increasing transformation risk.